Project Summary/Abstract Objective: This project aims to elevate electron beam therapy (EBT) technology, which provides effective radiation treatment for superficial cancers (depth<6 cm), to that of other external beam radiotherapies (XRT), e.g. x-rays and protons, by bringing electron intensity modulation into the clinic. Challenge: Approximately 10% of radiotherapy patients (173,000 in USA annually) receive EBT for a portion of their treatment, and as many as 10% of these (17,300 annually) might benefit from bolus electron conformal therapy (BECT), which conforms the distal 90% dose surface to the cancerous planning target volume (PTV), protecting adjacent healthy tissue. Currently, radiation oncologists are limited in using BECT because PTV dose spread can be as great as 30% due to irregular bolus surface. This can be reduced to 10% by spatially modulating incident electron beam intensity. Heretofore, electron intensity modulation delivery technology has been unavailable. Innovation: Using our research collaborator’s recently invented electron intensity modulator design, Phase I demonstrated proof-of-principle for a PRIME (Passive Radiotherapy Intensity Modulator for Electrons), a low cost technology for which .decimal developed a fabrication method. PRIME consists of a matrix of small- diameter, cylindrical tungsten island blocks imbedded in a low-density foam in the beam-defining, collimating aperture. Varying diameters of island blocks placed on a hexagonal grid achieves desired intensity modulation. However, because current treatment planning systems (TPS) cannot manage PRIMEs, an electron TPS needs to be developed as well. Research Design: Phase II specific aims include (1) refining the pencil beam redefinition algorithm used for dose calculation under island blocks, (2) creating and evaluating an electron specific TPS, COMET-Plan (Computer Optimized & Modulated Electron Therapy Planning), which plans intensity modulated bolus electron conformal therapy (IM-BECT) and conventional EBT, managing treatment aids such as skin collimators and eye shields, (3) developing factory and clinical PRIME quality assurance methods, (4) performing a multi-institutional treatment planning study to determine the degree to which IM-BECT improves BECT dose plans, and (5) validating IM-BECT planning and delivery by comparing doses measured in anthropomorphic phantoms with planned (calculated) doses. Health Benefit: PRIME devices and COMET-Plan software will allow a new technique, IM-BECT, which provides uniform dose conforming to the PTV, resulting in (1) equally high chance of cancer control, (2) equally or better low chance of acute normal tissue complications, and (3) decreased chance of secondary cancers. For some patients, this will provide a better dose distribution than other XRT modalities, such as volumetric arc therapy or helical tomotherapy, improving their cancer treatment. Commercialization: As the world’s leading company producing patient-spe...